Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)

Dana E. Rathkopf, Matthew R. Smith, Johann S. De Bono, Christopher J. Logothetis, Neal D. Shore, Paul De Souza, Karim Fizazi, Peter F.A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Hendrik Van Poppel, Joan Carles, Thomas W. Flaig, Eleni Efstathiou, Evan Y. Yu, Celestia S. Higano, Mary Ellen TaplinThomas W. Griffin, Mary B. Todd, Margaret K. Yu, Youn C. Park, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan, Fred Saad

    Research output: Contribution to journalArticleResearchpeer-review

    202 Citations (Scopus)

    Fingerprint Dive into the research topics of 'Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)'. Together they form a unique fingerprint.

    Medicine & Life Sciences